Genmab Data From Pivotal Phase 3 EPCORE FL-1 Study Of Epcoritamab In Combination With Rituximab And Lenalidomide Demonstrates Consistent, Sustained Efficacy Benefits Throughout Clinically Relevant Subgroups

Loading news article.

Genmab Data From Pivotal Phase 3 EPCORE FL-1 Study Of Epcoritamab In Combination With Rituximab And Lenalidomide Demonstrates Consistent, Sustained Efficacy Benefits Throughout Clinically Relevant Subgroups | WAPE

Genmab Data From Pivotal Phase 3 EPCORE FL-1 Study Of Epcoritamab In Combination With Rituximab And Lenalidomide Demonstrates Consistent, Sustained Efficacy Benefits Throughout Clinically Relevant Subgroups

Article summary

Related companies

Comments —